Skip to content

Express Gratitude

Opportunity

Clinical trial participants and their care partners often do not feel valued for their contribution to clinical trials, which may impact retention, participant satisfaction, and overall adherence. Receiving an act of appreciation (e.g., a thank you card / letter) during a clinical trial is directly related to overall satisfaction with the clinical trial.

Considerations to Help Action the Opportunity

  • Include decisions around gratitude as part of the engagement strategy early in the clinical development planning process
  • Understand which tools and templates are most appropriate to your study and patient population 
  • Test gratitude tools with the patient population
  • Define distribution methods and understand how use of decentralized trials / platforms may impact which format is used
  • Identify opportunities to evaluate the value of the tactics and how they were received by participants / care partners (e.g., incorporating questions regarding gratitude into the SPFQ or similar patient feedback questionnaire)

Value and Potential Benefits

  • Improves recruitment from word-of-mouth referrals by participants speaking positively about their experience in clinical trials 
  • Improves engagement, adherence, and compliance by recognizing the time and effort participants contribute to the clinical trial 
  • Increases participant’s satisfaction and perceived value of their clinical trial journey by recognizing the value of their experience
  • Improves relationships with clinical research staff by recognizing the important relationship they develop with the patient and work needed to make the trial successful at their site
  • Improves industry reputation and trust in clinical research 

Related Blog Posts

Enough, already: the problem with clinical trial data collection

The clinical research ecosystem has never been more technologically capable — or more burdened by its own ambition. In December 2025, the Tufts Center for the Study of Drug Development and our team at TransCelerate published research that suggests nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are…

2026 DIA Global Annual Meeting: What the FDA’s Real-Time Data Push Actually Means for Sponsors and CROs

In this video interview from the 2026 DIA Global Annual Meeting, Kevin Bugin, head of global regulatory policy and intelligence at Amgen and executive sponsor of TransCelerate’s Embedded Pragmatic Trials initiative, reframes the FDA’s continuous review expectations around real-time evidence generation and explains why quality by design—not data cleanup—is what regulators are now demanding. Watch…